United States

BMI View: Investor perception of Pfizer during 2012 will be dominated by four key factors: the successful divestment of its non-core nutritional and animal health assets, whether the... 2012-02-02

BMI View: Abbott Laboratories has an enlightened appreciation of the two major current trends in the global pharmaceutical market. The US-based company is performing well in emerging... 2012-02-01

BMI View: We think 2011 was a very good year for Bristol-Myers Squibb (BMS). It outperformed all other companies in terms of share price performance, it has a very strong product pipeline... 2012-01-30

BMI View: Multinational pharmaceutical companies will open more manufacturing facilities in Foreign Trade Zones (FTZs) in Puerto Rico to benefit from the low tax rate and below-average... 2011-12-15

BMI View: US sales of Lipitor (atorvastatin) will drop by less than expected following patent expiry. This is due to the many franchise preservation strategies employed by Pfizer, namely... 2011-11-30

BMI Core View: Drugmakers will increasingly use differential pricing in emerging markets. Pharmaceutical companies generally price their patented medicines at the maximum the market... 2011-11-18

BMI View: Pfizer's decision to shed its nutrition and animal health businesses will be welcomed by investors, who are displaying preferences for pure-play pharmaceutical companies.... 2011-11-04